ERBB2 and invasive ductal breast carcinoma: There were significantly more invasive ductal carcinoma (97.3% vs. 95.0%) and less invasive lobular carcinoma (1.0% vs. 4.0%) in the HER2‐low group compared to the HER2‐zero group (p = 0.019).